Loading provider…
Loading provider…
Urology Physician in Tampa, FL
NPI: 1437240983Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get MD Scott's Phone Numberphone_androidMobile
Get MD Scott's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2008 - 2026
MI State Medical License
2005 - 2009
NY State Medical License
2005 - 2006

American Board of Urology
Urology
University of Michigan
Residency • Urology
2005 - 2008
University of Michigan School of Public Health
MS • Clinical Research Design and Statistical Analysis
2005 - 2007
New York Presbyterian Hospital (Cornell Campus)
Residency • Urology
2001 - 2005
New York Presbyterian Hospital
Internship • Transitional Year
2000 - 2001
Brown University
BA • History of Art and Architecture
1992 - 1996
Vagelos College of Physicians and Surgeons
vagelos.columbia.edu
Medical School
Until 2000
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 52000Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | 157 | 252 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 65 | 65 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 35 | 42 |
| 4 | 52204Biopsy of the bladder using an endoscope | 35 | 36 |
| 5 | 52234Destruction and/or removal of (0.5 to 2.0 centimeters) small growths of the bladder using an endoscope | 27 | 27 |
Authors: Gilbert, Scott M, Dunn, Rodney L, Wei, John T
Journal: J Urol
Authors: James Mckiernan, Mitchell Benson, Jared Whitson
Journal: Urology
Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy.
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Intervention / Treatment: OTHER: Surveys
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: CG Oncology, Inc., Richard M. Shulze Family Foundation
Intervention / Treatment: DRUG: Nivolumab, DRUG: CG0070